title: Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
abstract: Cordycepin has been shown to interfere with a myriad of molecular processes from RNA elongation to kinase activity, and prevents numerous inflammatory processes in animal models. Here we show in a mouse model of LPS-induced acute lung injury that cordycepin prevents airway neutrophilia via a robust blockade of expression of several inflammatory genes, including the adhesion molecule ICAM-1 and VCAM-1, the cytokine/chemokine MCP-1, MIP-1α, MIP-2 and KC, and the chemokine receptor CXCR2. Such a blockade appears to be related to a severe reduction in TNF-α expression. Interestingly, in an in vitro system of A549 epithelial cell inflammation, cordycepin effectively blocked LPS-induced, but not TNF-α-induced, VCAM-1 expression. Such effects correlated with a marked reduction in p65-NF-κB activation as assessed by its phosphorylation at serine-536 but without an apparent effect on its nuclear translocation. The effects of cordycepin on the expression of VCAM-1 and ICAM-1, and of NF-κB activation and nuclear translocation upon TNF-α stimulation resembled the effects achieved upon poly(ADP-ribose) polymerase (PARP) inhibition, suggesting that cordycepin may function as a PARP inhibitor. Indeed, cordycepin blocked H(2)O(2)-induced PARP activation in A549 cells. In a cell-free system, cordycepin inhibited PARP-1 activity at nanomolar concentrations. Similar to PARP inhibitors, cordycepin significantly induced killing of breast cancer susceptibility gene (BRCA1)-deficient MCF-7 cells, supporting its therapeutic use for the treatment of BRCA-deficient breast cancers. With added antiinflammatory characteristics, therapies that include cordycepin may prevent potential inflammation triggered by traditional chemotherapeutic drugs. Cordycepin, to the best of our knowledge, represents the first natural product possessing PARP inhibitory traits.
authors: The Stanley Scott Cancer Center, and the Department of Pharmacology and Experimental Therapeutics; Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA.
authors: Hogyoung
authors: H
authors: Kim
authors: Amarjit S
authors: AS
authors: Naura
authors: Youssef
authors: Y
authors: Errami
authors: Jihang
authors: J
authors: Ju
authors: A Hamid
authors: AH
authors: Boulares
references: Trends Pharmacol Sci. 1999 Apr;20(4):171-81
references: 10322503
references: Eur Respir J. 2009 Feb;33(2):252-62
references: 18829681
references: Clin Exp Allergy. 2008 May;38(5):839-46
references: 18261157
references: Clin Breast Cancer. 2009 Jun;9 Suppl 2:S73-81
references: 19596646
references: J Immunol. 2006 Nov 1;177(9):6489-96
references: 17056581
references: Cardiovasc Res. 2008 Jun 1;78(3):429-39
references: 18245064
references: Cell Signal. 2008 Jan;20(1):186-94
references: 17993261
references: Cell Mol Life Sci. 2002 Sep;59(9):1534-53
references: 12440774
references: Pharmacol Res. 2002 Feb;45(2):73-85
references: 11846617
references: Biol Chem. 1999 Jul-Aug;380(7-8):953-9
references: 10494847
references: Biochem Pharmacol. 2010 Dec 15;80(12):1869-77
references: 20417190
references: Curr Opin Oncol. 2009 Sep;21(5):412-9
references: 19553815
references: J Biol Chem. 2010 Jan 22;285(4):2610-21
references: 19940154
references: J Pharmacol Exp Ther. 2009 Apr;329(1):150-8
references: 19124646
references: Eur J Pharmacol. 2006 Sep 18;545(2-3):192-9
references: 16899239
references: EMBO J. 1999 Aug 16;18(16):4446-54
references: 10449410
references: N Engl J Med. 2009 Jul 9;361(2):123-34
references: 19553641
references: Cell. 2003 Jun 13;113(6):677-83
references: 12809599
references: PLoS One. 2009 Oct 13;4(10):e7430
references: 19823587
references: Pharmacol Res. 2005 Jul;52(1):72-82
references: 15911335
references: J Infect Dis. 2005 Nov 1;192(9):1658-65
references: 16206083
references: J Pharm Pharmacol. 2005 Dec;57(12):1509-19
references: 16354395
references: J Immunol. 2010 Aug 1;185(3):1894-902
references: 20610652
references: Am J Respir Cell Mol Biol. 1998 Dec;19(6):881-91
references: 9843922
references: Am J Respir Cell Mol Biol. 2003 Mar;28(3):322-9
references: 12594058
references: Shock. 1996;6 Suppl 1:S23-6
references: 8828094
references: Breast Cancer Res. 2009;11(6):111
references: 20017885
references: Cell Cycle. 2007 Apr 15;6(8):962-71
references: 17404506
references: Nat Rev Cancer. 2002 Apr;2(4):301-10
references: 12001991
references: Cardiovasc Drug Rev. 2007 Fall;25(3):235-60
references: 17919258
references: J Leukoc Biol. 2009 Dec;86(6):1385-92
references: 19741160
references: Mol Cell. 2007 Jan 26;25(2):297-308
references: 17244536
references: Cancer Res. 1998 Oct 15;58(20):4510-4
references: 9788591
references: Circulation. 2007 May 8;115(18):2442-50
references: 17438151
references: Allergy. 2011 Jul;66(7):853-61
references: 21276008
references: Front Biosci. 2008 Jan 01;13:2400-7
references: 17981721
references: Am J Pathol. 2008 Jul;173(1):2-13
references: 18535182
references: Am J Physiol Lung Cell Mol Physiol. 2002 Dec;283(6):L1247-54
references: 12388356